Aug. 8, 2014
3SBio Inc. announced on Aug. 8, 2014 that it entered into an exclusive license agreement with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).
In addition to an upfront payment, milestone payments will be made along the clinical development and registration path. 3SBio will also pay DiNonA a sales-based royalty.
In China, there are currently about two to three million AL patients. Among them, between 30,000 and 40,000 patients are newly diagnosed each year. Patients are currently treated with traditional chemotherapy and bone marrow transplants, both of which have major side effects.